Advertisement

Topics

The Center for Biosimilars Company Profile

01:05 EDT 23rd October 2018 | BioPortfolio

The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other authoritative industry voices, to share information on emerging technologies, with a focus on improving critical thinking in the field to affect patient outcomes. The Center for Biosimilars®, which was cited in a United States Senate testimony on drug prices and out-of-pocket costs for rheumatoid arthritis drugs, discusses the current landscape for advanced healthcare management.


News Articles [944 Associated News Articles listed on BioPortfolio]

Biosimilars development moving to Asia

Biosimilars manufacturing is moving to Asia with biosimilars developed in Korea contributing 43% of the global biosimilars value. This has been a quick expansion from the total share of 0% back in 201...

Biosimilars applications under review by EMA – June 2018

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval of...

The Center for Biosimilars® Launches Interview Series With Biosimilars Expert

The Center for Biosimilars®, an online resource for emerging therapies that focuses on improving patient outcomes, launched its latest video interview series featuring Sheila Fra...

Recommendations for biosimilars in rheumatology in the Middle East

The increasing availability of biosimilars in Middle Eastern regions may provide an opportunity to increase the number of rheumatology patients who have access to traditionally more expensive biologic...

ICS Opens New 3PL Distribution Center

New flagship distribution center to serve pharma manufacturers of specialty medications, biosimilars, cell and gene therapies

How will the US market respond to Coherus’s two new biosimilars?

Biosimilars, or highly similar versions of high-price biologics, continue to grab market headlines with their sales potential. However, Coherus BioSciences’ biosimilars...Read More... The post How ...

Interchangeability for biosimilars

Dr Daniel F Alvarez, Senior Director at Pfizer, gave a presentation on interchangeability for biosimilars at the Drug Information Association’s (DIA) Biosimilars Conference, which was held on 24−2...

Interchangeability is an obstacle to the use of biosimilars in the US

According to Professor Richard Frank from the Department of Health Care Policy, Harvard Medical School, Boston, USA, there are several factors that may account for the slow development of the market f...

Drugs and Medications [0 Results]

None

PubMed Articles [582 Associated PubMed Articles listed on BioPortfolio]

Biosimilars: Expert consensus of the Latin American Society of Psoriasis (SOLAPSO) in Argentina.

With the appearance of biological treatments, therapeutics has changed in many rheumatological, dermatological and oncological diseases. Due to the high cost of these biological medicaments and the ex...

Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the oppo...

Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?

Availability of biologic disease-modifying antirheumatic drugs (bDMARDs) has improved clinical outcomes in rheumatoid arthritis, but it also increased the cost of treatment. Biosimilars, the regulated...

Opportunities and challenges in biosimilar uptake in oncology.

There are now 10 approved biosimilars in the United States, including 3 oncology drugs, and at least 16 others in late-stage development. The introduction of competition into the biologic space launch...

The nocebo effect: a clinical challenge in the era of biosimilars.

The nocebo effect is defined as a negative effect of a pharmacological or non-pharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological ac...

Clinical Trials [1709 Associated Clinical Trials listed on BioPortfolio]

Post-ASCT Use of Zarzio®

There are limited data concerning the use of biosimilars of filgrastim in autologous stem cell transplantation (ASCT). This study aimed to evaluate G-CSF efficiency and safety (based on ha...

An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital

The objective of this study is to analyze the factors influencing the medical and non-medical direct costs of patients treated with biotherapy during the last twelve months (infliximab or ...

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

This study is a multicenter, prospective, single-arm, phase II study to evaluate the antitumor activity and safety of trastuzumab biosimilar (herzuma®) plus gedatolisib in patients with H...

An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

The purpose of this program is to provide early access to ustekinumab where it is commercially unavailable for the treatment of participants with moderately to severely active Crohn's dise...

Evaluation of Functionnal Improvement After Spa Therapy in Fontcaude Center

Evaluation of functionnal improvement after spa therapy in Fontcaude center, for knee osteoarthrtis Background. Knee osteoarthritis is the first indication of spa therapy in rheumatology. ...

Companies [1394 Associated Companies listed on BioPortfolio]

The Center for Biosimilars

The Center for Biosimilars® is a digital resource that serves as a platform for health economic experts, managed care professionals, key clinical specialists and other a...

FINOX AG

FINOX pioneers niche Biosimilars and wants to establish itself as a respected competitor in these markets. Through our Biosimilars to come we aim to create value for patients, partners and the inve...

AAM Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosi...

Lynkogen Inc.

Alteogen Inc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-dug conjugates, biobetters and b...

Alteogen Inc.

Alteogen lnc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as ADCs, biobetters and biosimilars. Alteoge...

More Information about "The Center for Biosimilars" on BioPortfolio

We have published hundreds of The Center for Biosimilars news stories on BioPortfolio along with dozens of The Center for Biosimilars Clinical Trials and PubMed Articles about The Center for Biosimilars for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Center for Biosimilars Companies in our database. You can also find out about relevant The Center for Biosimilars Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record